We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002252
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
  Purpose
To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.

Condition Intervention
Diarrhea HIV Infections Drug: Octreotide

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients must have the following:

  • Uncontrolled diarrhea that is either a manifestation or complication of documented HIV infection.
  • Ability to communicate, participate, and comply with the requirements of the study.
  • Capability of self administering injections of study medication or have responsible family member or companion who can.
  • Given written consent prior to study entry.

Prior Medication:

Required:

  • At least two weeks of conventional dosing regimens of antidiarrheal medication (e.g.:
  • Lomotil, Imodium, Paregoric) within one month prior to study entry. OR Patients with evidence of upper or lower GI infection(s) for which there is approved, potentially curative therapy must have failed appropriate treatment for at least two weeks.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Evidence of underlying immunosuppressive disease other than due to HIV.
  • Diarrhea caused by a known gastrointestinal disorder such as idiopathic ulcerative colitis, Crohn's disease, acute stool culture positive bacterial colitis (documented within the last 2 weeks prior to study entry AND not having at least 2 weeks of antibiotic therapy), pseudomembranous colitis (Clostridium difficile toxin positive), short gut syndrome, chronic pancreatitis (alcoholic or idiopathic), ischemic bowel disease, or enteroenteric fistulae.

Patients with the following are excluded:

  • Diarrhea that can be controlled with conventional antidiarrheal agents.
  • Stool weight at either of the 2 baseline periods that average < 500 g/day.
  • Evidence of underlying immunosuppressive disease other than due to HIV.
  • Diarrhea caused by other gastrointestinal disorders not related to HIV.

Prior Medication:

Excluded:

  • Previously treated with Sandostatin as an anti-diarrheal agent.
  • Experimental antidiarrheal drugs within one month of study entry.

Present intravenous drug abuse.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002252


  Show 23 Study Locations
Sponsors and Collaborators
Sandoz
  More Information

Publications:
Romeu J, Miro JM, Mallolas J, Sirera G, Tortosa F, Clotet B. Sandostatin (SMS-201-995) in the long-term management of chronic diarrhea in AIDS patients. Int Conf AIDS. 1991 Jun 16-21;7(2):272 (abstract no WB2362)

ClinicalTrials.gov Identifier: NCT00002252     History of Changes
Other Study ID Numbers: 102A
D203
First Submitted: November 2, 1999
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Last Verified: August 1992

Keywords provided by NIH AIDS Clinical Trials Information Service:
Octreotide
Diarrhea
Acquired Immunodeficiency Syndrome
AIDS-Related Complex

Additional relevant MeSH terms:
HIV Infections
Immunologic Deficiency Syndromes
Diarrhea
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Octreotide
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents